Literature DB >> 31015245

Thoracic involvement of diffuse lymphangiomatosis successfully treated with sildenafil.

Arnaud Maurac1, Marie-Pierre Debray2, Bruno Crestani3,4, Camille Taillé3,4.   

Abstract

General lymphatic anomaly (GLA) is a very rare disorder, characterised by multifocal lymphatic malformations into various tissues that is due to congenital abnormalities of lymphatic development. No treatment has ever proved its efficiency.We report a 22-year-old man with recurrent bronchial casts due to thoracic involvement of GLA. After a 6-month treatment with sildenafil (20 mg three times a day), a phosphodiesterase 5 inhibitor, chest CT scan showed a complete regression of ground-glass opacities and lung function test results improved substantially and remained stable for 1 year. The treatment was well tolerated.This observation suggests that sildenafil may be a therapeutic approach to be tested in thoracic involvement of GLA. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: respiratory system; interstitial lung disease

Mesh:

Substances:

Year:  2019        PMID: 31015245      PMCID: PMC6510121          DOI: 10.1136/bcr-2018-228523

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Sildenafil for severe lymphatic malformations.

Authors:  Glenda L Swetman; David R Berk; Shreyas S Vasanawala; Jeffrey A Feinstein; Alfred T Lane; Anna L Bruckner
Journal:  N Engl J Med       Date:  2012-01-26       Impact factor: 91.245

2.  Successful treatment of diffuse pulmonary lymphangiomatosis with bevacizumab.

Authors:  Jurjan Aman; Erik Thunnissen; Marinus A Paul; Geerten P van Nieuw Amerongen; Anton Vonk-Noordegraaf
Journal:  Ann Intern Med       Date:  2012-06-05       Impact factor: 25.391

3.  Plastic Bronchitis Related to Idiopathic Thoracic Lymphangiectasia. Noncontrast Magnetic Resonance Lymphography.

Authors:  Sanaâ El Mouhadi; Camille Taillé; Aurélie Cazes; Lionel Arrivé
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

4.  Dual signals underlying diabetic lymphatic barrier dysregulation.

Authors:  J Steven Alexander; Felix Becker
Journal:  Cardiovasc Res       Date:  2015-05-20       Impact factor: 10.787

Review 5.  Thoracic involvement in generalised lymphatic anomaly (or lymphangiomatosis).

Authors:  Francesca Luisi; Olga Torre; Sergio Harari
Journal:  Eur Respir Rev       Date:  2016-06

6.  Sildenafil for microcystic lymphatic malformations of the head and neck: A prospective study.

Authors:  John C Koshy; Bradley S Eisemann; Nikhil Agrawal; Sheena Pimpalwar; Joseph L Edmonds
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2015-04-09       Impact factor: 1.675

7.  Propranolol as a treatment option in Gorham-Stout syndrome: a case report.

Authors:  Vered Nir; Ludmila Guralnik; Galit Livnat; Ronen Bar-Yoseph; Fahed Hakim; Anat Ilivitzki; Lea Bentur
Journal:  Pediatr Pulmonol       Date:  2013-09-02

Review 8.  Congenital chylothorax treated with oral sildenafil: a case report and review of the literature.

Authors:  D T Malleske; B A Yoder
Journal:  J Perinatol       Date:  2015-05       Impact factor: 2.521

9.  Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.

Authors:  Takayuki Kimura; Tatsuo S Hamazaki; Makoto Sugaya; Shoji Fukuda; Techuan Chan; Miwa Tamura-Nakano; Shinichi Sato; Hitoshi Okochi
Journal:  J Dermatol Sci       Date:  2014-01-21       Impact factor: 4.563

10.  Lymphatic Malformation in Newborns as the First Sign of Diffuse Lymphangiomatosis: Successful Treatment with Sirolimus.

Authors:  Nicola Laforgia; Federico Schettini; Delia De Mattia; Domenico Martinelli; Grazia Ladisa; Veronica Favia
Journal:  Neonatology       Date:  2015-10-28       Impact factor: 4.035

View more
  1 in total

1.  Effective Initial Treatment of Diffuse Pulmonary Lymphangiomatosis with Sirolimus and Propranolol: A Case Report.

Authors:  Ieva Dimiene; Kristina Bieksiene; Jurgita Zaveckiene; Mindaugas Andrulis; Daiva-Elzbieta Optazaite; Neringa Vaguliene; Marius Zemaitis; Skaidrius Miliauskas
Journal:  Medicina (Kaunas)       Date:  2021-11-29       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.